Podcast appearances and mentions of David Brennan

Former Vatican correspondent Juliet Linley on the moment of Cardinal Robert Prevost’s election to the papacy. Then: our guests Elisabeth Braw and David Brennan discuss the 80th anniversary celebrations of Victory Day.See omnystudio.com/listener for privacy information.

We hear from ‘The Atlantic’ about what this week has been like in the newsroom since Signal-gate. Our panelists David Brennan and Terry Stiastny discuss the House hearings on the intelligence leak, examine the upcoming US trip to Greenland and look at the future of European security as Spain announces plans to boost defence by summer. Plus: on this day in 1830 the Book of Mormon was published. See omnystudio.com/listener for privacy information.

David Brennan, stiúrthóir bainistíochta castle books i gCaisleán a Bharraigh ag labhairt faoi leabhair don Nollaig.

On this episode of What The Tech from Boast AI, we're thrilled to welcome onto the show entrepreneur-extraordinaire David Brennan!  David is the CEO and Co-Founder of Arkeo AI, which is a SaaS Copilot that enables sales teams to achieve faster win rates and ultimately close more deals. More than just a sales tool, Arkeo AI is designed specifically for SaaS founders and their teams to make informed decisions and drive growth. As customers integrate their systems, Arkeo offers AI Agents tailored to specific departments that continuously analyze data and deliver actionable insights while also alerting to opportunities and threats.  As powerful as the Arkeo AI solution is, this is hardly David's first go-round in the entrepreneurship space. He holds an Executive MBA with a specialization in Innovative Leadership, co-founded Safety Evolution in 2016, and helped execute the strategic acquisition of SafetyTrek in 2022 before embarking on the Arkeo Ai journey.  It's an impressive career to date, and David shares some of his expertise for building a successful AI business in 2024, and what's on deck for the future. Boast AI accelerates the success of innovative businesses globally with software that integrates financial, payroll, and engineering data into a single platform of R&D intelligence. Visit Boast.ai, sign up for our Blog newsletter and follow us on LinkedIn for weekly #InnovatorsLive sessions and the latest news to fuel your growth. Intro and Outro music provided by Dennis Ma whose mixes you can find on Soundcloud at DJ DennyDex.

Aoife Barry, Author and Freelance journalist discusses the much anticipated release of Sally Rooney's latest book "Intermezzo", while our reporter Sheila Naughton spoke to David Brennan of Castle Book Shop in Mayo, home to Sally Rooney.

This month, Brixton Red brings you a plethora of seductive and scintillating sounds from around the world, across the decades and through the genres. From bossa beats to dynamic dub; from jazz-rap to disco dabblings; from funky breaks to wholesome house, the July episode of Brixton Red's Sounds of the City has got it all. Join me!Tune into new broadcasts of Brixton Red, Third Wednesday from 2 – 4 PM EST / 7 - 9 PM GMT.For more info visit: https://thefaceradio.com/brixton-red//Dig this show? Please consider supporting The Face Radio: http://support.thefaceradio.com Support The Face Radio with PatreonSupport this show http://supporter.acast.com/thefaceradio. Join the family at https://plus.acast.com/s/thefaceradio. Hosted on Acast. See acast.com/privacy for more information.

David Brennan is a source of resilient leadership lessons, an innovative entrepreneur, and a dedicated advocate for female founders. Hailing from the Yukon Territories, David's leadership qualities were honed through sports and later refined through personal and professional growth. Despite early academic challenges due to ADHD, he achieved a significant transformation by completing an online MBA with distinction, which reignited his passion for lifelong learning. As the founder of Arkeo AI, David is revolutionizing business operations with a SaaS co-pilot that integrates AI to enhance efficiency. His leadership philosophy is rooted in mindfulness, using his running practice to stay grounded and focused. David is committed to fostering diverse teams and empowering female leaders, recognizing the unique balance they bring to the business world. Connect with David on LinkedIn to follow his inspiring journey and learn from his wealth of experience. Listen & Subscribe on: iTunes / Stitcher / Podbean / Overcast / Spotify Contact Info Website: arkeoai.com/ LInkedIn: David Brennan Most Influential Person Stephanie, a spiritual leader and performance coach Effect On Emotions Mindfulness has allowed me to truly feel emotions. For a long time, as a man, showing emotions was frowned upon, so I just boxed them up and didn't feel them. That's not a healthy way to live. As I've become more mindful and aware of what's happening around me, I've been able to actually experience my emotions. This has been incredibly healthy and surprisingly fun because life is pretty dull without feeling it all. Thoughts On Breathing I struggle with meditation and am not very good at it, but running serves as my meditation. It helps me manage my ADHD and expend energy. However, I've discovered some amazing breathwork exercises that everyone should try. For instance, Andrew Huberman talks about the sympathetic sigh, which can help relieve a cramp while running. I also practice box breathing regularly. Just six weeks ago, I was in Zion National Park, feeling like I was about to fall off a 1,500-foot mountain. I sat down and did 10 minutes of box breathing, which centered me right into the moment. Breathwork is one of the most powerful tools anyone can use. Bullying Story Bullying is a complex issue. I remember bullying someone as a kid and having a deep conversation with a teacher afterward. That moment made me realize that wasn't the kind of person I wanted to be, and it stuck with me. In the oil and gas industry, I saw so much of this toxic behavior. The environment was so harsh that showing any emotion meant you'd be torn down. One reason I left oil and gas was because of this toxicity. In the tech world, I can create safer, more supportive teams. It's crucial to foster an environment where inappropriate behavior is addressed. Unhappy people often act out, leading to bullying and a toxic workplace. Being aware and connected with your team helps prevent these issues and promotes a healthier work culture Suggested Resources Book: The Mountain Is You by Brianna Wiest App: Othership Breathwork App App: Sam Harris Breathwork App Related Episodes Mind, Mountains, and Mental Health; Mike Schauch A​​n Architect's Mindful Life Vision; Lance Cayko The 200% Life; Adam Hergenrother Offer From Bruce Seeking relief from stress and anxiety? As a coach and hypnotist, I'm here to help you conquer your inner critic so you can confidently thrive. Email me at bruce@mindfulnessmode.com with ‘I Am Determined' for a free coaching session. Let me help you pave the way to a fulfilling life.

Brixton Red brings you sounds from all over the world, across the genres and through the genres. This month's show includes Venezuelan dub, seventies soul, barbecue-coated funk, deep disco, party hip hop and Afro beats by the yard. Including new releases from the Harlem Dance Club and Coney Island Rhythm Band and prime cuts from Flash Callaghan, Sly5thAvenue and Solazz. Phew, what a scorcher!Tune into new broadcasts of Brixton Red, Third Wednesday from 2 – 4 PM EST / 7 - 9 PM GMT.For more info visit: https://thefaceradio.com/brixton-red//Dig this show? Please consider supporting The Face Radio: http://support.thefaceradio.com Support The Face Radio with PatreonSupport this show http://supporter.acast.com/thefaceradio. Join the family at https://plus.acast.com/s/thefaceradio. Hosted on Acast. See acast.com/privacy for more information.

Nadine Batchelor-Hunt and David Brennan discuss Brazil recalling its ambassador to Israel, whether Trump-aligned Supreme Court justices should recuse themselves, the scaling down of London's only local daily and whether we'd trust Uber with a trip to sample Champagne. Plus: a letter from DjiboutiSee omnystudio.com/listener for privacy information.

Springtime is here, and with it we have the May episode of Brixton Red's Sounds Of The City on The Face Radio. Full to the brim with eclectic, electric sounds from the best in soul, roots reggae, funk, new wave, breaks, hip hop, world music, nu-funk and soulful house. Beats for the elite!Tune into new broadcasts of Brixton Red, Third Wednesday from 2 – 4 PM EST / 7 - 9 PM GMT.For more info visit: https://thefaceradio.com/brixton-red//Dig this show? Please consider supporting The Face Radio: http://support.thefaceradio.com Support The Face Radio with PatreonSupport this show http://supporter.acast.com/thefaceradio. Join the family at https://plus.acast.com/s/thefaceradio. Hosted on Acast. See acast.com/privacy for more information.

From Brixton via Brooklyn to the world, April's edition of Brixton Red travels around the globe, across the decades and through the genres to bring you the best sounds around. This month's show covers classic soul, jazz-tinged new wave, psychedelic reggae, consciousness rap, funky breaks, deep disco, house and nu-funk, leading to a climax of Asian-inspired bangers. Includes new releases from Pecoe, Jitwam and Patawawa.Tune into new broadcasts of Brixton Red, Third Wednesday from 2 – 4 PM EST / 7 - 9 PM GMT.For more info visit: https://thefaceradio.com/brixton-red//Dig this show? Please consider supporting The Face Radio: http://support.thefaceradio.com Support The Face Radio with PatreonSupport this show http://supporter.acast.com/thefaceradio. Join the family at https://plus.acast.com/s/thefaceradio. Hosted on Acast. See acast.com/privacy for more information.

Brixton Red leads us into the Spring with a wildly diverse selection of tunes from around the world, through the decades and across the genres. This month's selection features new wave, classic soul, drum & bass, hip hop, dancehall, classic disco, world music, house and funky breaks. South London calling....Tune into new broadcasts of Brixton Red, Third Wednesday from 2 – 4 PM EST / 7 - 9 PM GMT.For more info visit: https://thefaceradio.com/brixton-red//Dig this show? Please consider supporting The Face Radio: http://support.thefaceradio.com Support The Face Radio with PatreonSupport this show http://supporter.acast.com/thefaceradio. Join the family at https://plus.acast.com/s/thefaceradio. Hosted on Acast. See acast.com/privacy for more information.

This week's Sounds of the City by Brixton Red aims to cover the whole gamut of musical experiences. A heady mix from jazz to soul, reggae to northern, hip hop to disco house, funky breaks to Kate Bush, new wave to electro-rockabilly and electro-swing to big room house...and everything in between the lines. Soul, funk, groove, chill, rock, back-a-yard, disco, beats, jazz, swing; you'll find all of that in there...but not necessarily in that orderTune into new broadcasts of Brixton Red, Third Wednesday from 2 – 4 PM EST / 7 - 9 PM GMT.For more info visit: https://thefaceradio.com/brixton-red//Dig this show? Please consider supporting The Face Radio: http://support.thefaceradio.com Support The Face Radio with PatreonSupport this show http://supporter.acast.com/thefaceradio. Join the family at https://plus.acast.com/s/thefaceradio. Hosted on Acast. See acast.com/privacy for more information.

The Vicky Phelan Campaign and Portrait Tour hosted by David Brennan, a childhood friend of Vicky's, along with Relay for Life Clare and Clare Haven Services is set to take place this Friday, January 26th. David will be joined on the night by Lahinch healthcare campaigner John Wall and 221+ member Caoimhe O'Neill-Forde. The free event will take place in Danlann an Chlair. Doors will open at 6.30 p.m. while the talk will begin at 7 p.m. For more on this, on Monday's Morning Focus, Alan Morrissey was joined by David Brennan, John Wall, Caoimhe O'Neill-Forde and Mary Howard.

Mixed-use project proposed for congested intersection Adeveloper has submitted plans to build two four-story, mixed-use buildings at one of Beacon's busiest intersections, the corner of Wolcott Avenue (Route 9D) and Beekman Street. If the project is approved, the developer would demolish a three-story commercial building - the former site of the Beacon Popmart, an art event space - and merge its lot with two vacant parcels. The two buildings would include 14,000 square feet of commercial space and 65 one- and two-bedroom apartments. The project also includes 89 parking spaces, some of which would be located beneath one of the buildings. The site is almost entirely within Beacon's Linkage District, a zone that the 2017 comprehensive plan says should promote residential development that reinforces connections between the Main Street and waterfront areas. Specifically, it instructs mixed-use development to be allowed adjacent to the intersection of Route 9D and Beekman Street to create "a more inviting and active pedestrian gateway between the Linkage District and Main Street." Developments such as the River Ridge townhouses, The View condominiums and the West End Lofts have been added to the area in recent years. A year ago, the Planning Board also approved the Beacon Commons, a 62-unit building that will be constructed at the corner of West Main and Bank streets, and the 246-apartment Edgewater complex is under construction a few blocks away. However, on weekday afternoons the area is also easily Beacon's most congested, as vehicles leaving the Metro-North station routinely back up almost to City Hall waiting to get to Interstate 84. A traffic consultant for the project acknowledged to the Planning Board, which began its review of the application on Tuesday (Dec. 12), that "there's some issues there," and suggested adding a traffic signal at Wolcott (which is known as North Avenue in that area) and Tompkins Avenue. A light would have to be approved by the state Department of Transportation. The consultant also suggested timing modifications for the existing signal at Wolcott and Beekman to better handle the traffic flow. Planning Board members were cautious. Kevin Byrne noted the importance of the intersection as one of the entrances to Beacon. "The city has an opportunity here to repair some of the damage done" decades ago by urban renewal, "which was significant," he said. "There's a real public interest in making this a significant building." One of the proposed buildings will also adjoin High Street, which "has a collection of some of the most stately Victorian homes" in Beacon, said Len Warner. "It's a gem of a street." "So don't mess it up," said John Gunn, the Planning Board chair. Cell tower approved The Planning Board on Tuesday approved an application by Verizon to erect a 120-foot cell tower in the Fairview Cemetery, about 400 feet from residences on Helen Court. Approval was granted despite protests from neighbors, who cited health concerns and its effect on property values. A Verizon attorney, David Brennan, told the board that the structure is necessary because a tower on Mount Beacon that provided coverage in the 1990s, when few people used cellphones, is no longer feasible. "It's too far away, it's too high up and it's too far from the population it's serving," he said. The new tower will have three "sectors," each with an antenna, plus three boxes that include overvoltage protectors and other equipment. Other wireless carriers could install antennas on the tower if there is a need, Brennan said. Verizon's lease on the site is for five years and will automatically renew, unless canceled by the company, for up to 25 years. 409 Fishkill Ave. Soka Gakkai International, a Buddhist organization, has submitted plans to repurpose 409 Fishkill Ave., a parcel owned by the Healey Brothers auto dealership, as a worship center that would accommodate up to 200 people. The parcel is one of four being vacated by Healey, whi...

John Brennan was tragically crushed to death on his family farm during Ireland's first coronavirus lockdown on the 23rd of April, 2020. The 13-year-old was driving down a steep and slippery slope at the farm when he lost control of the tractor, causing it to overturn and roll almost 30 meters before landing on its side. Embrace Farm provides a caring and supportive network for all those affected by farm accidents in Ireland and helped John's parents and the rest of the Brennan family in their time of need. Alan Morrissey was joined in studio by Sharon and David Brennan, parents of John Brennan, and the Brennan's neighbour, John Vaughan from Mooghna Milk. If you need support or help following a sudden death or injury on the farm, you can contact Embrace FARM for support on 085-770-9966. Picture (c) by Vinicius Souza from Vinícius Rodrigues de Souza via Canva

An Ennistymon resident admits she still waits to see her son smile through the back window three years on from his tragic death in a farm accident. It comes ahead of an event this month in aid of Embrace Farm, which offers support to farm families impacted by injury and death. John Brennan was just 13 years old when the tractor he was driving overturned on April 23rd 2020, leaving him with fatal injuries. The incident took place on his family farm after he had told his parents he was helping out on a neighbour's farm. It's understood John was driving down a steep portion of the farm when he lost control of the vehicle, causing it to overturn and slide almost 30 metres, which resulted in him being crushed to death. John's father, David Brennan says one of the most difficult aspects is not knowing why he undertook the journey. According to HSA data, farm accidents made up 50% of all workplace deaths last year, with 12 such fatalities having taken place across the country. Farm vehicles and machinery accounted for 59% of deaths, with falls from heights, falling objects and slurry drowning also being significant contributing factors. John Brennan's mother Sharon says that more than three years after her son's tragic death, they are still grappling with the reality of never seeing him again. A Tractor Run will get underway in Lahinch on Wednesday, December 27th in aid of Embrace Farm, which is Ireland's only support network for farm families impacted by injury and death, and currently supports over 400 farm families nationwide. Ennistymon farmer John Vaughan, who's involved in Moonagh Milk and is organising the event, believes the work the organisation does is invaluable to the farming community.

Labhair Niamh linn faoi na gradaim a bronnadh ag an deireadh seachtain do chomhlachtaí i Maigh Eo a chuireann an Ghaeilge chun cinn. Agus labhair David Brennan ó Castle Books & Jen McGee ó Ionad Ealaíona Halla an Línéadaigh faoin mbealach ina gcuirean siad fhéin an teanga chun cinn ina n-ionad oibre.

For this episode of the PepTalks Podcast, we welcome David Brennan, Executive Chair of Nexus Vehicle Rentals for the second time to discuss his continuing journey with the business. David was CEO of Nexus for 9 years and steered the company through 3 PE transactions before recently transitioning to Exec Chair. We discuss how to drive organic growth through effective sales and marketing, developing your management team and succession planning for the CEO role.

On this week's Alive & Kicking podcast: Clare speaks to Christine Clinton, founder of the 'Christine Clinton Cancer Care' who is also chair of the 'Christine Clinton Wellness For Children' initiative and is the woman behind the inaugural 'Children Health Summit'. Together they discuss reaching our children in the formative years and teaching them the benefits of being healthy. David Brennan on continuing the legacy of his lifelong friend, Vicky Phelan, by telling her story, educating young people on cervical cancer, and raising funds for charity. And radio star Christian O'Connell appeared to have it all but not everything was as it seemed. He joins Clare to talk about his experience with panic attacks, reassessing what his goals were in life, and how breathing exercises helped him along the way.

Case IH is adding to its lineup of planters with the 2110 Early Riser planter and an updated version of the 2150 Early Riser planter. David Brennan, Case IH planter marketing manager, was on site at the National Farm Machinery Show this past week at Louisville, Kentucky, to discuss the planters with RealAgriculture’s Bernard Tobin.... Read More

A special look-back to some of the guests Miriam spoke to during 2022 - Anne Enright, Brian Cox, Vicky Phelan with Vincent Devine and David Brennan, Kieran and Orla Walsh, Patrick Kielty, John Boorman with Brendan Gleeson, Phil Coulter

On today's show we pay tribute to Vicky Phelan Ray speaks to friends of Vicky's Lorraine Walsh and David Brennan and The Stunning were one of Vicky's favorite bands Steve Wall from the band joins Ray and Conor Pope is back in studio with Pricewatch.

Cervical cancer campaigner Vicky Phelan has died at the age of 48. David Brennan, lifelong friend of Vicky Phelan joined Clare McKenna on Lunchtime Live to remember his friend and the legacy she has left behind... Image: vickyphelanportrait.com

See omnystudio.com/listener for privacy information.

In the second part of the 2022-23 Social Justice Statement - Respect: Confronting violence and abuse, the Bishops examine the drivers and enablers of domestic and family violence - the inequalities between men and women and attitudes such as condoning violence, dominance and control over women by men. Sherry Balcombe, manager of Aboriginal Catholic Ministry Victoria shares her views, including how colonisation has affected Aboriginal communities. Finally, the Bishops call for changes in the church's own culture and state that the misuse of religious teachings to justify violence and abuse against women and children is sinful. Download the Statement and associated resources here. David Brennan reads the statement. --- Send in a voice message: https://anchor.fm/office-for-social-justice/message

In the final part of the 2022-23 Social Justice Statement - Respect: Confronting violence and abuse, the Bishops highlight the current resources, programs and advocacy movements working to eradicate domestic and family violence. Building community capacity to support the change in attitudes needed is key, and many Catholic services are working in this area through practical supports for victim/survivors and children, and reformation programs for perpetrators. They conclude that the roots of violence lie in the abuse of power to control and dominate others. They acknowledge the findings of the Royal Commission into Institutional Responses to Child Sexual Abuse that cultural factors within the church have enabled abuse in the church and call for the reformation needed to enable us to be true to the Good News of Jesus. Download the Statement and associated resources here. David Brennan reads the statement. --- Send in a voice message: https://anchor.fm/office-for-social-justice/message

In the third part of the 2022-23 Social Justice Statement - Respect: Confronting violence and abuse, the Bishops examine how Jesus rejects any use of religious teaching to condone violence and the need to address the direct violence taking place as well as indirect violence. The Bishops state that indirect violence, made up of cultures and attitudes condoning violence, abuse and control are structures of sin and must be changed. The Bishops directly address beliefs held by some Christians that men are the 'head of the household' who can control women and children and they state that this is wrong. The relationships between spouses should reflect their equality in Christ and all family members deserve to be treated as Christ would. Perpetrators should take responsibility and transform themselves using the support available. Download the Statement and associated resources here. David Brennan reads the statement. --- Send in a voice message: https://anchor.fm/office-for-social-justice/message

In this first part of the 2022-23 Social Justice Statement - Respect: Confronting violence and abuse, Archbishop Timothy Costelloe, President of the Australian Catholic Bishops Conference denounces domestic and family violence. The Bishops highlight the staggering prevalence of domestic and family violence and the groups most affected by it. We also hear directly from women affected, Shirleen Campbell and Rosie Batty. Download the Statement and associated resources here. David Brennan reads the statement. --- Send in a voice message: https://anchor.fm/office-for-social-justice/message

Professor David J. Brennan is the Associate Dean, Research at Factor-Inwentash Faculty of Social Work, University of Toronto. He is the founder and director of the CRUISElab, an interdisciplinary, community-based social work research lab dedicated to addressing the sexual, mental, physical, and emotional health of gay, bisexual, two-spirit, cis- and trans-gender men who have sex with other men (GB2M). Dr. Brennan has been directly involved in the HIV epidemic since 1983 in many social work roles, including case manager, clinical supervisor, psychotherapist, program manager, and researcher. Learn more about his research here and follow him on Twitter here.In this podcast we talk about the history of HIV stigma as well as stigma towards GB2M. We talk about what this stigma looks like in a day-to-day experience of getting dressed and walking down the street, as well as how it can be embedded in policies and practices. Using current examples of the recent changes in eligibility of GB2M in donating blood in Canada, and discourse around Monkeypox, David reminds us of how we can all engage in challenging stigma.Episode hosted by Dr. Carmen Logie. Supported by funding from the Canada Foundation for Innovation and Canada Research Chairs program. Original music and podcast produced by Jupiter Productions, who have various production services available to support your podcast needs.

In this episode of the podcast, Jenny is joined by the artist Vincent Devine, who recently travelled the country with his painting ‘The Vicky Phelan Triptych,' and its owner, David Brennan. Vincent attended WIT's International Women's Day celebrations, where he talked the audience through the symbolism of each section of the painting, and the collaborative process that he and Vicky went through during its planning and development. He discusses the importance of the painting in generating conversations around women's health, trauma and resilience, and how it has impacted his own life and work. During the episode, Jenny and Vincent also discuss Dr Christa de Brún's poem, “Triptych in Blue” written about the artwork.

NVP Francesca Amante joins CEO & Founder, David Brennan of Safety Evolution as they discuss entrepreneurship and leadership in the workplace. David dives into the core attributes of growing a team that is built on trust, integrity and longevity. David speaks on the importance of embracing failure, and to ultimately allow your team to thrive by getting out of their way. Whether you are growing a board of directors such as in JCI , or building a team in the business world, being a leader that leads by example rather than with words, is so powerful. Enjoy this episode as we welcome this inspiring leader and CEO to our podcast stage. --- Send in a voice message: https://anchor.fm/jci-canada/message

Miriam is joined by artist Vincent Devine who's painting of cancer campaigner Vicky Phelan was unveiled in Vicky's hometown of Mooncoin last week. Miriam is also joined by Vicky and Vicky's friend David Brennan who purchased the painting raising funds Heroes Aid, a charity dedicated to helping healthcare workers during the pandemic.

The year is 2006 and the nominees are: 1. Reese Witherspoon - Walk the Line 2. Felicity Huffman - Transamerica 3. Charlize Theron - North Country 4. Judi Dench - Mrs Henderson Presents 5. Keira Knightley - Pride & Prejudice In 2006 Reese Witherspoon won the Oscar for Best Actress for playing June Carter-Cash in the Johnny Cash bio pic, Walk the Line. Many people compare this win to Julia Roberts in that they don't understand how she swept the award circuit for this role. I have seen this film many times and I've always loved Reese in it. Is a lead Oscar win? We discuss more on the podcast episode. Felicity Huffman gives one of the best performances in Transamerica. It's sad to see her movie career didn't continue to live up to the success of this film. Charlize Theron was nominated for ‘North Country' a movie about female factory workers in Minnesota and the harassment they endure. Keira Knightley was nominated for Pride & Prejudice and so began her slew of historic film roles. Finally, Judi Dench was nominated in one of the most confusing movies I have ever seen, Mrs Henderson Presents. Join host Kyle Brownrigg with guest host David Brennan as they discuss.

Alan speaks with Dr. David Brennan, professor, Factor-Inwentash Faculty of Social Work at the University of Toronto, about Netflix employees walking out earlier this week after their streaming giants handling of Dave Chapelle's anti-transgender comments. See omnystudio.com/listener for privacy information.

David Brennan, CEO of Carers Tasmania

The year is 2016 and the nominees are: 1. Brie Larson - Room 2. Charlotte Rampling - 45 Years 3. Cate Blanchett - Carol 4. Saoirse Ronan - Brooklyn 5. Jennifer Lawrence - Joy - In 2016 Brie Larson won the Best Actress Oscar for Room, the story of a girl and her son held captive for 7 years in a small shed. This was an extremely stacked year. I'll admit, I had a hard time picking a winner for this episode. The other nominees included Saoirse Ronan for Brooklyn, Cate Blanchett for Carol, Jennifer Lawrence for Joy, and the dark horse of the year, Charlotte Rampling for 45 Years. Join host Kyle Brownrigg with guest host David Brennan as they discuss. . . . . . . . . . . . . #bestactress #supporting #oscars #academyawards #hollywood #silverscreen #vintage #gay #queer #lgbtq #canada #losangeles #gaypodcast #robbed #snubbed #film #movie #podcast #supporting #lead #brielarson #room #charlotterampling #45years #cateblanchett #carol #saoirseronan #brooklyn #jenniferlawrence #joy

David Brennan reads the first part of Cry of the Earth, Cry of the Poor the Australian Catholic Bishops Conference Social Justice Statement 2021-22. In this section, the Bishops recount the signs of the times through the eyes of those who are most affected. They listen to the voices of fire fighters, farmers, members of communities reliant on extractive industries, the First People and young people. They pay attention to the voices of our neighbours in the Pacific and to the voice of creation. Download the Statement and associated resources here. --- Send in a voice message: https://anchor.fm/office-for-social-justice/message

David Brennan reads the second part of Cry of the Earth, Cry of the Poor the Social Justice Statement 2021-22 of the Australian Catholic Bishops Conference. In this section, the Bishops draw on Scripture, the theological tradition, Catholic Social Teaching, and human wisdom - including the insights of First Peoples - to inspire and ground authentic Christian responses. Download the Statement and associated resources here. --- Send in a voice message: https://anchor.fm/office-for-social-justice/message

David Brennan reads the third section of Cry of the Earth, Cry of the Poor the Australian Catholic Bishops Conference's Social Justice Statement 2021-22. In this section the Bishops commit to a seven-year journey towards total sustainability guided by the Laudato Si' Goals. They encourage Catholic families, parishes, schools, dioceses and organisations to join them by signing up on the Laudato Si' Action Platform. Download the Statement and associated resources here. --- Send in a voice message: https://anchor.fm/office-for-social-justice/message

Today on Lifestyles, Lillian has a conversation with David Brennan, Founder and Executive Director of Vouch4Vets, a platform helping veterans and their families find employment. David shares challenges veterans face when looking for employment and how the Vouch4Vets video referral program highlights veterans' valuable skills and experience.

Join Oliver as he chills with comedian, actor, writer and storyteller David Brennan! In addition to being extremely funny, David has also created and performed several awesomely imaginative one man shows. He has hosted film festivals, comedy shows and concerts and also has experience as a journalist. David was also a member of beloved Canadian sketch comedy troupe 'The Imponderables' for 12 years, performing at Just For Laughs and winning five Canadian comedy awards! The episode kicks off with talk about the upcoming 'Crack Up Comedy Festival', which boasts a killer lineup that includes David. The discussion then shifts to 'Bill & Sons Towing', a fantastic web series that starred David and his sketch comedy comrades. Oliver learns about some of the many interesting twists and turns of David's journey as an entertainer, as well as his deep dedication towards the projects that he chooses to work on. The chat also touches on hecklers, vaccines and technology, with a ton of laughs along the way! Recorded on March 25th, 2021 Audio/Visual Production by Zoom Edited (poorly) by Oliver George ARCADE- Oliver: 13 / Guests: 5 (No match, Zoom)

Joined by our good friend David, we have a great conversation on his college takeaways and how community has been such an important part of life. Also in this episode we try and answer, "Why are we seeing a decline of men in the church?" Ask us your questions at fromour20@gmail.com

It’s always insane to me that Susan Sarandon only has one Oscar. She won her Academy Award for Dead Man Walking co-starring Sean Penn. Sarandon plays a real life nun asked to be a spiritual guide to a convicted rapist and murderer on death row. Her competition included Meryl Streep who got the mom juices flowing in The Bridges of Madison Square County, Sharon Stone as Ginger, a no bullshit hustler, in Casino, Elizabeth Shue in Leaving Las Vegas, and Emma Thompson in Sense and Sensibility. This was a very difficult year to pick a winner. We were divided. Who would you pick? . Join host Kyle Brownrigg with guest host David Brennan as they discuss.

Our guests this morning are David Brennan from the Manhattan Beach Education Foundation and Jill Lamkin, Executive Director for the Downtown Manhattan Beach Business & Professional Association. David Brennan is the Director of Development & Partnerships at MBEF. He is responsible for establishing and maintaining partnerships between MBEF and the local community, including parents, PTAs, and businesses throughout the South Bay and beyond. Focused on implementing solicitation strategies for new and increased donations, David connects prospective partners with the programs and leadership of MBEF.  Jill Lamkin is the Executive Director for the Downtown Manhattan Beach Business & Professional Association. Jill oversees marketing, advocacy, and community relations for all businesses licensed within Downtown Manhattan Beach. The Downtown Business + Professional Association is a non-profit organization dedicated to serving the needs of over 250 retailers, restaurants, and local businesses. This morning, our guests will tell us about the Downtown Manhattan Beach Gives Back Day taking place on Wednesday, November 11, when 11% of sales will be donated to MBEF from participating locations in Downtown MB. =+=+=+=+=+=+ To Find Out More about the two show hosts of The South Bay Show read on: Jackie Balestra features a comprehensive selection of things to do, places to go and people to know in the South Bay.to learn more visit http://www.SouthbayByJackie.com To Find Out More about Joe Terry visit http://www.ForeverMemoirs.com What's Happening in the South Bay, South Bay, Hermosa Beach, Manhattan Beach, Redondo Beach, The South Bay Show, Los Angeles, California, Current Events Calendar, Torrance, El Segundo, Palos Verdes

On Friday's program, we addressed a range of breaking news items, starting on a heart-warming note. We spoke to Scott Mitchell of the Erie Zoo about how the Zoo is navigating the pandemic and the arrival of a new red panda. Then we turned to the bayfront as Joel interview David Brennan about the ongoing decision-making on the changes PennDOT is proposing for the connection between the Bayfront Parkway and State Street. Finally, as the country is shocked over the President contracting COVID-19, Dr. Brad Fox of Liberty Family Practice discusses his experience with coronavirus patients.

This episode of the podcast is a little different to what you've come to expect.  David Brennan and his father founded the International Boxing Concierge in 2011. The purpose of this business was to link boxing champions and fans together for an experience that money can't buy. We're talking private dining, cocktail parties, golf days and training experiences with names like Mike Tyson, Roy Jones Jnr, Evander Holyfield, George Foreman, Roberto Duran and Jeff Fenech. David shares enough stories to paint a little picture of what it might have been like to party in Vegas with these legends and how much damage these lads can do to a bar tab.  Prior to sharing these stories David and myself had a little chat about what life is like living in Melbourne during these times and how it has affected his business, Radium Capital. This is a good one, I hope you all enjoy. https://www.facebook.com/theartofsurrenderpodcast/ https://www.instagram.com/artofsurrenderpodcast/

To Live Life to the Full: Mental health in Australia today is the Social Justice Sunday Statement of the Australian Catholic Bishops Conference for 2020. You can access a print version here. The Statement encourages faith communities, governments and each one of us, to make mental health a priority. It is a timely message in the context of the COVID-19 pandemic. The pandemic is affecting many members of our parishes, schools and communities. Understanding mental health will help us to be aware of those who need our support. The Statement encourages us all to reject stigmatisation, to work for the transformation of social determinants of mental ill-health, and to call for policies and service provision that meets the needs of the poorest and most marginalised members of our community. In this episode, David Brennan reads the second of three sections of the Statement. Section Two: The Great Project of Community Integration, recalls the history of mental health care in Australia. It affirms the objective of deinstitutionalisation but points to gaps in community care. --- Send in a voice message: https://anchor.fm/office-for-social-justice/message

To Live Life to the Full: Mental health in Australia today is the Social Justice Sunday Statement of the Australian Catholic Bishops Conference for 2020. You can access a print version here. The Statement encourages faith communities, governments and each one of us, to make mental health a priority. It is a timely message in the context of the COVID-19 pandemic. The pandemic is affecting many members of our parishes, schools and communities. Understanding mental health will help us to be aware of those who need our support. The Statement encourages us all to reject stigmatisation, to work for the transformation of social determinants of mental ill-health, and to call for policies and service provision that meets the needs of the poorest and most marginalised members of our community. In this episode, David Brennan reads the third and final section of the Statement. Section Three: We are All in this Together, points to the action needed by faith communities, governments, and all of us to make mental health a priority. --- Send in a voice message: https://anchor.fm/office-for-social-justice/message

To Live Life to the Full: Mental health in Australia today is the Social Justice Sunday Statement of the Australian Catholic Bishops Conference for 2020. You can access a print version here. The Statement encourages faith communities, governments and each one of us, to make mental health a priority. It is a timely message in the context of the COVID-19 pandemic. The pandemic is affecting many members of our parishes, schools and communities. Understanding mental health will help us to be aware of those who need our support. The Statement encourages us all to reject stigmatisation, to work for the transformation of social determinants of mental ill-health, and to call for policies and service provision that meets the needs of the poorest and most marginalised members of our community. In this episode, David Brennan reads the first of three sections of the Statement. Section One: The Mental Health of our People and Communities provides an overview of the challenges that we face. --- Send in a voice message: https://anchor.fm/office-for-social-justice/message

David Brennan is the Managing Shareholder for Brennan & Associates. With over 55 years of combined legal experience in Pennsylvania and New Jersey, each of their attorneys brings a unique skill set to our practice.  While all of their attorneys are active in the practice of Workers’​ Compensation Defense, each has his own practice focus as well.  These areas include Family Law, Criminal Law, Business Law, Employment Law and all aspects of Liquor Law.  Our client base includes insured entities, self-insured entities, small business owners and individuals.  Additionally, our referral network provides further resources for clients with more unique needs such as Estate Planning and Bankruptcy. They recognize that no two clients have identical needs.  For this reason, they remain flexible in how they approach all matters from billing arrangements and rate structures to staffing so that each client receives tailor-made service.  No detail is overlooked in ensuring that our service matches each client’s specific needs. They are pleased to be able to provide legal representation in multiple jurisdictions. Their Pennsylvania practice is based primarily in Berks and its surrounding counties, but we also represent clients from Wayne County to Bradford County, and to Pittsburgh and its surrounding counties.  Their Moorestown, New Jersey, office is centrally located and allows us to appear in all vicinages from Atlantic City to Paterson.

On the Monday program, Joel welcomed two new members of Erie City Council to talk about their stories and the challenges they face in their capacity of representing the citizens of the largest city in the northwestern quarter of the commonwealth. Our guests were Michael Keys, who ran for and won the office in 2019, and David Brennan, who was appointed by the current Council members after a rigorous recruiting and vetting process.

https://www.youtube.com/watch?v=AgUJQtQUrEs IDEA Pharma: A Conversation with Dr. Menelas Pangalos of AstraZeneca Mike Rea:                          Just a quick note this is Menelas Pangalos, can I have your official title? Dr. Menelas Pangalos:       I am EVP of Innovative Medicines and early development. I’m at Biotech Unit and also Global Business Development. Mike Rea:                          Okay, we’ll get on to innovative medicines. This is obviously one of the series of Idea collider interviews with people with actually very interesting thoughts on innovations. Dr. Menelas Pangalos:       Hopefully. Hopefully interesting. Mike Rea:                          Definitely interesting and hopefully very useful for the viewers. So, actually let’s starts with our first question, what does AstraZeneca means by innovative medicine? Dr. Menelas Pangalos:       Yes that's probably the most difficult question because innovation is different things to many people, & I’m sure - I remember when first joined the company & was walking around the site’s; looking at project’s & people were telling me about their innovative programs & they actually - you know, if you think about this as a competitive sport, I think our view of innovation when I first joined was personal best versus world records, And when I think of innovation, I think of world records. You know, you’re cutting edge, the cold face of innovation in terms of whatever area you’re in, whether it’s a technology or whether it’s a therapy area. Disease understanding is actually - you’re making the discoveries rather than following discoveries. Mike Rea:                          So, that was an almost an internally referenced versus external referenced. Dr. Menelas Pangalos:       Yeah, so exactly they were very inwardly as an organization we were incredibly inwardly focused & we were getting better internally but when your benchmark is very low, you’re getting better on a very low benchmark actually it’s isn’t getting you anywhere near where you need to be. So, one of the big shifts in our culture which I think is helpful in our innovation is being much more outwardly focused. Seeing what’s happening as a consequence, understanding where we should be pushing ourselves to be even better & who we should be working with to enable us to build on whatever it is that we choose to do. Mike Rea:                          That’s interesting & the innovative medicines group is focused on forward looking pipeline -? Dr. Menelas Pangalos:       Yeah, So I run everything from the first target ideation all the way to proof of concept. So, we have to hand over to our latest [inaudible 02:28] organization programs that are ready for phrase III. So, everything from - you know the basic disease understanding – to therefore give you the new targets so you identify & optimizing those programs to generate molecules that are ultimately suitable for phrase III investment. So, there’s therapy area-based research, then we also have our technology platform group to support the therapy areas  Mike Rea:                          And you’re essentially then combining ways of doing that with choices that you’ve made along the way of which areas to focus on itself. Dr. Menelas Pangalos:       Choices all the way & one of the things - the big shifts that we made, which actually we made when Pascal joined the company at the end of 2012 is really focus down on the areas where we thought we could be globally competitive or we could be setting world records not personal bests, & so, we really focused organization down on to sort of oncology, cardiovascular, metabolic & renal disease. Which there’s a lot of overlap & than respiratory disease & there’s couple of areas that we not dabbled in but we have small – relatively small investments, less than 5% of our budget goes on there in neuroscience & infections where we tend to pawn all those program with other companies where that’s their core area of competence & where they want to be leading from an innovation perspective. Mike Rea:                          ok, that’s interesting. So, it’s more like the British Olympic teams approach the winning gold medals. where we can win gold and…  Dr. Menelas Pangalos:       Go deep & yes, it’s been very interesting because, as we’ve gone deep and as we’ve got more & more focused in those areas. You see that actually you’re starting to build a depth of knowledge & a depth of pipeline that really does make you quite competitive in that space, & the quality of the partnership – you can create the quality of the people who you recruit – the quality of the decision making it all gets better because the commercial organizations also lined up the same way. For me it was like the organization was never all - but I always thought of us as iron filings all going in different directions. When we focus organization on those three core areas, everyone’s thoughts then point in the same direction & they understood, well good looking [inaudible 04:44]  Mike Rea:                          Yeah, & it’s been interesting. you mentioned when Pascal took over but it seems to be in a purposeful shift at AstraZeneca, because for a long time it wasn’t my favorite company. But this certainly - your publications & the kind of pursuit of a kind of directed improvement Has been clear from the outside. Do you have the room to do that? Dr. Menelas Pangalos:       Yeah, look I mean - I was hired by the CEO before Pascal joined, a guy called David Brennan who was a super smart guy, very commercially driven. They’ve built a great company with an amazing brand Seroquel, Nexium, Crestor. And what’s interesting is most of those were me too or me better drugs, but nevertheless, very successful in their time & what David realized when he hired me was that the R&D organization wasn’t where it needed to be & they had to try & re-invent themselves & I was the one of the first recruits to try & help with that reinvention.  Mike Rea:                          What was the first thing that you had to do under that new regime? Dr. Menelas Pangalos:       Yeah, it was a challenging [blank] - activity wasn’t particularly high so one of the things that I tried to really get the organization bought into reasons why we need to change, to learn from what we’ve done before. So, we looked at all of the projects that were run from 2005 - 2010. We were spending about 5 million dollars a year on R&D. And really trying to look at what differentiated a successful project from a non-successful project. obviously, we had a lot more unsuccessful projects. Mike Rea:                          What was your definition of successful? Dr. Menelas Pangalos:       Launch.   your medicine launching or moving into late stage of development at least. But actually, launching is the most important one & looking at what data – what information we have & how programs actually progressed from candidate nomination all the way through to phase III. And what we saw was – actually when we did the analysis, if you measured us by the number of things that we were doing, the numbers of candidates that we’re putting into the clinic or the number of R&D's that we were filing. We were one of the most productive companies in the industry. Secondly only to Pfizer after it had acquired Wyeth. But if you measured us by the number of launches that we had – we were the second least productive company in industry. So clearly there was a disconnect. Our science was getting rewarded, but there were no medicines coming out at the other end & that’s what we had to fix it.                                          The take-way message from all of this work was quality over quantity. It’s the quality of what you work on not the quantity of what you do. And then as we dug further there were five things or we call a five R framework that we thought, based on the data that we analyzed would improve your probability of running a successful program and they’re pretty obvious I have to say, pretty intuitive & yet actually quite difficult I think to execute on consistently.                                          So, the first of the five R's is around the right target. How well do you understand the biology of the target that you work on? how well do you understand the disease pathophysiology? How it connects – relates to path whether you’re trying to modulate? What genetic validation do you have either in pre-clinical animal models or in human genetics & how do your scientists consequently try to prove or importantly disapprove Your hypothesis. are they asking those killer questions to try and invalidate, not just validate there’s something for hypothesis? Mike Rea:                          Yeah. So how important is that almost adversarial nature? Dr. Menelas Pangalos:       It’s really important actually rewarding your scientists for disapproving things as much as approving things & making good decisions – good kills is actually something that we’re very passionate about and very proud about & we celebrate as well.  As I’ll say in a moment the reason why we’re failing now the most is actually because of lack of efficacy in phase II, which means we still don’t understand the targets and the pathways well enough. But we’re getting better, so that’s perhaps the most important of all of the 5 R's. Mike Rea:                          Okay. I think we talked about this a little bit before that we’ve reframed this role and we're calling it failure; we call the process of early phase – development asymmetric learning. Can you learn faster & better than the other guys? Dr. Menelas Pangalos:       Exactly. Mike Rea:                          And if you call it learning it’s not trying to failing anymore. Dr. Menelas Pangalos:       It’s exactly right & making sure that you fail, you haven’t spent too much money & you don’t just keep on - cause what we were very good at what we saw as we had – our science was very creative. Finding ways of getting to the next hurdle & just for the sake of getting the next hurdle, cause that’s where we're being measured on. So right target, second one right issue. When you have a molecule whether it’s a monoclonal antibody or small molecule or the drug modality, demonstrate first of all in the preclinical models that you can engage the target & understand what your PK / PD relationships are. So, understand you’ve got to inhibit a kinase in a tumor? Do you have to inhibit that kinase for 24 hours? Do you have to inhibit it at 50%, 80%, 100%? Really understand what the relationship is in order to generate the efficacy you are after & then even more importantly you have to have a way of measuring that in the clinic. If you can’t demonstrate target engagement in a clinic, we have a big problem, because then if you fail you have no idea if it’s your molecule is cramp or lousy - excuse my French - or if your hypothesis is wrong. So, a good failure is for me is ones who I know have demonstrated target engagement but the molecule didn't work so biology is wrong. Right. And we hardly had any ways of demonstrating proof medicines – so a number of phase II that we were running. where the molecules failed and you asked the question – I remember these first six months in project meeting, so it didn't work – did we engage the target? Did the receptor antagonist get into the brain? If it’s a schizophrenia program and quizzical blank stares from everybody saying - we have no idea.  Mike Rea:                          Oh, so you weren't learning well.  Dr. Menelas Pangalos:       So, you weren't learning anything, not well, you weren't learning anything actually because you had no idea why you are failing, so that doesn't happen anymore. The third one is right safety, so again because our scientists were being rewarded for number of candidates, they were remarkably good - working how to lower the doses to the minimum amount, where they now – because they're not measuring target engagement, engaging the target but they still get the candidate through. And what we saw was that when you had early safety signals, they invariably came back to bite you somewhere during early development or even worse later stage development. So, waiting out your safety signals early, making sure you are working on the right series, on the right scaffolds, that you understand both your target-based toxicity and your molecule-based toxicity, really, really important. So, we spent a lot of time developing our safety models. Fourth of the five R's right patient. To find the patient population in which your medicine is most likely to work. Because if It doesn't work in that patient population, it's not going to work on a broader patient population, and we were again very good at going into broad patient populations. What we saw actually was that as the programme moved through the clinic, the commercial organization got into full steam ahead and wanted to go into broader bigger. Of course AstraZeneca was very much a primary cadre of an organization and so what we saw actually in the data was that the scientists were becoming less confident about their projects and the commercial folks were becoming more confident because the big yourselves the number is getting bigger, but you know a 100% of nothing is not a very big number. So that was the other pieces - to find the patient population and do that experiment first and develop it there and then other things will happen. This is not different, advanced for example we have been doing for quite some time, and then finally the last of the 5R’s is right commercial. By right commercial, I don’t mean is it going to be a billion dollar pick yourselves - what I mean is why would anyone want to take or prescribe the medicine and why would anyone want to reimburse it. So, understanding what your comparators need to be, understanding what the standard of care will be in the time frame that you are going to be launching. It’s a very difficult thing to do, often 10 - 15 years ahead but really challenging the teams to think about where that puck will be when the programmes moves through the clinic or when it launches to make sure they are being ruthless about the comparisons they do. This now goes back to the conversation around being outward looking versus inward looking. And then it was interesting, when we submitted the paper for review, one of the comments that came back from one of the reviewer's was - well if you do all of this you need to add a 6th R which is the right culture. Because what you are actually doing is changing the culture of the company and so you need to talk about how it back ships and he was actually, he or she was actually right because as we start to implement  the 5 R's to every governance meeting we have, through  every project review that we do, what you start to see is is the culturing shifting from one where science is being rewarded for just numbers of candidates, to they are being rewarded for proof of mechanism, for proof of concept, for launches, for diagnostic strategies and for publishing great research papers and it has shifted the culture from one that's being very inwardly focused, personal best to one that's outwardly focused, more collaborative and hopefully setting a few world records. Mike Rea:                          Which is interesting. So, we, did you use incentive structure as a lever or was that a kind of after effect of getting people to focus in the right place? Dr. Menelas Pangalos:       So the incentives changed and our global incentives in the company actually changed when Pascal joined where we didn't just have R&D incentives, we had incentives around R&D - which were phase 3 investment decisions, launches, phase II starts, and there's assessing of commercial goals which are around the growth drivers of the company which you can land everybody up in oncology, cardiovascular, metabolic, respiratory etc. and then  some financial goals and we were thrust to meet our objectives, we have to get all of these things - not just the R and D ones. So, the whole organizations actually got very well lined up. But for us the things that we rewarded scientists on were:- the quality of the work they were doing, so these good kills, or good moving forward in a CD package, coming forward you know a lot less candidates coming forward every year than we ever had, we were no longer the most prolific, but the quality was much higher and the teams had to be able to cover every aspect of the programme including what the developing plan looks like going forward to proof of concept. And then the successes, their rewards came and they demonstrated proof of mechanism, demonstrated proof of concept, when they get the phase III investment decision because I don't get to decide what goes into phase III, someone else has to put that through and so that you can’t game the system in that way. Mike Rea:                          Yes. Interesting. We have always quoted the Brazil Germany World Cup final, cause as you look at the goals, clearly very big divide, but actually Brazil won the game on all of the surrogate metrics. They shot some goals, shot some targets, possession Brazil won.   Dr. Menelas Pangalos:       But the goals count. Launching drugs count. So, the launching drugs counts and of course the challenges is, when you are in a research team launching a drug somewhere away. We were lucky that we had a few drugs that moved quite fast through the whole process. So, people got a sense that we could actually do this and then the other piece that was a very important measure actually for us is actually just the quality of the publications coming out of the organization. And if you look at where we were, I had an organization of about 5000 people when I joined and we were publishing about 200 papers and one nature or science paper. Today we are half that size, we are about 2500 people, we are publishing between 40 - 50 nature science sell papers a year. So even those, and of course when I first joined it was impossible, you couldn’t do drug discovery and good science, now it’s part of our DNA. Mike Rea:                          It’s all the same thing. Dr. Menelas Pangalos:       Yeah and people don't even question that, and of course what happens as a consequence of doing it is, people want to come and work with you, whether it is an academic collaborator, whether it is Biotech or whether it’s someone who actually wants to be a part of AstraZeneca.  Mike Rea:                          Of course  Dr. Menelas Pangalos:       So it’s made a huge shift to us and of course our move down to Cambridge is all part of that shift, it’s part of being close to an academic hotbed where there is amazing science because we have become much more open than we ever were, which for me again it’s part of my DNA in terms of being collaborative. Being collaborative in Cambridge is really, really easy because there is so many people you can collaborate with. And of course we have Oxford, London in our doorstep and the rest of the UK and the rest of the world, we have tried to join UK and Sweden together to try and create a European hub and the partnerships we have now which when we have many and some quite unusual, we actually have AstraZeneca scientists work in the same lab as an academic scientist, shared goals and they are working on basic research as well as drug discovery programs. It’s made us much, much more porous than we have ever been. Mike Rea:                          The thing I mentioned to you before was, we have been doing the pharmaceutical innovation index for 9 years now. And if you look where AstraZeneca started to where Astra Zeneca came number 1 this year. It’s been a rapid turnaround. I think because all the things that you recognize and our index measures, did you launch and did you launch successfully? Did you get reimbursement?  So clearly you have gone from that period when you were doing a lot of internal R&D anywhere to suddenly getting somewhere. Dr. Menelas Pangalos:       And it’s been - the wins are important. Celebrating the wins when you get them is actually one of the things that galvanized the organization. But you know, I think that are the three key things, being really focused on high quality science, being really collaborative and open, and then executing flawlessly when it comes to moving through the pipeline and launching. Mike Rea:                          When you said, you came up with the five R’s. Was that a process to come up with or were those the five things that mattered the most or did you go in with -? Dr. Menelas Pangalos:       No actually look, you know Pfizer had published their three pillars,  these things are very intuitive and most interesting is people ask me about - because these are you know, they're bleeding obvious, you’d think everybody would do it, people ask me - why do you publish this, because it’s like a trade secret. They're not! Everybody should be doing this and I think many companies do, but Actually many companies don’t and when I ask people that join us from other companies about what's different about the way that we do it versus others, it’s that we really do practice this. I don't let well not I; we don't let programs come forward if the odds don't look good, and if they do come forward with a gap, let’s say we’re not sure about right safety, we have a question mark about whether we’re going to have the right dose versus safety liability. It’s the first question we ask in the clinic. So, do you really understand the proof of mechanism, the PKPD and workout the margins, so it really focuses the attention is you understand where your liabilities are in a program to go there first and workout whether you can flip a red to an amber or green –  Mike Rea:                          So, it’s okay to go at risk as long as you –  Dr. Menelas Pangalos:       As long as you know what the risk is and you're very clear about what the killer experiment is. Mike Rea:                          Hoping it’s not there. Dr. Menelas Pangalos:       Yeah and then of course the first few years projects will come and you say no once, you say no twice, you take teams through it and teams change their behavior. Mike Rea:                          Oh, you do mean it? Dr. Menelas Pangalos:       Yeah, yeah. Doesn’t make a difference. It’s kind of important, right. There's got to be some tease to it. Mike Rea:                          So, is there a definition of innovation at AstraZeneca? Because one of the things we always find is that everyone has a different approach to what it is and what it means. Dr. Menelas Pangalos:       As I said earlier, it means so many things to different groups. So, for my precision medicine group, innovation would be developing the first plug-based DNA test for EGFO - it’s very different to my oncology therapy, it should be looking to identify a new target or pathway and get the first molecules or the first crystal structure that target with the molecule. So I think innovation really is different things to different groups, I think as I said earlier the most important thing is that whatever we choose to do and whichever areas we’re focusing, whether its Crispr or whether its Protacs or whether it’s a new – some other drug modanity or something around new safety models that improve our prediction, that we are aware of what's out there, so we’re not re-inventing the wheel. We’re working with the very best people and we’re pushing the boundaries of science so that when hopefully we’ve cracked something, when we publish it, people aren't saying ‘so what’. I’d really like us to be viewed as driving science forwards and not just helping ourselves but actually helping the fields that we work in also get better at what they do, and that culture piece is really important because it’s one of the things that I think can make us a little bit different. When we moved to Cambridge, our new building in Cambridge is right in the Addenbrookes campus, the Addenbrookes hospital, its next to the Papworth hospital and then on the other side we’re opposite the laboratory for microbiology, the MRC microbiology. More Nobel laureates than any other institution in the world and an incredibly, if you want high powered science that's one of the places to go in the world and I was talking to John Savalo at the time, he was the CEO of the MR center, ‘wouldn’t it be great, given that we’re going to be in Cambridge to see if we can start working with the MRC, with the LMB’ and so we put a small pot of money together that we co funded and I went and saw Hugh Pelham who was the director at the time and I said, let’s try and do something and of course his natural first inclination was well you know, we’re all very, very smart and you're from industry and we don't want you to suck our brains dry and us get nothing back. Which I think is – I think pharma has moved on a long way over the past few years but I think still in some circles the [inaudible 23:55] of what we do and how we work – and so we worked really, really hard to build a strong relationship with the LMB and to actually make it a very easy way to get – we created this pot of money that basically PI’s from AZ and the LMB, to come and apply for, and they can get a post doc and it’s a two pager and it would be very, very quick and easy and not bureaucratic and Hugh and myself would review this and we’d say yes or no. Based on the quality of the science. Mike Rea:                          Together? Dr. Menelas Pangalos:       Together, we did it together. And it was – of course the first round was not particularly well subscribed but today we work with more than half the PI’s in the LMB, collaboratively, and they get back as much as – because they can see that we can do things, we can create molecules for them, we have certain capabilities and technologies that they don't have access to, but more importantly there's actually a lot of overlap in terms of our common interest. And so, when you put us both together, we actually get more powerful because we’re obviously quite plad in our thinking, they're quite basic in their thinking, we put it together and actually magic happens, and we've got some amazing stuff that's going on working with them.  Mike Rea:                          Which is an interesting – I think your comfort with ‘open’ is an interesting differentiator for you in that way that you described this long-term approach, proof of concept if you like of going in. Have you found it easy to have your scientists behave the right way in the collaboration? Dr. Menelas Pangalos:       It’s been an evolution right, because initially we were incredibly closed. We didn't want to share anything. Everything was proprietary and you just do it in baby chunks and you chip away, you chip away and eventually people get comfortable and there's many examples, of course we had to do it – because if you think of where we were and having to try and change the culture quickly, one of the best ways of changing the culture is actually bringing external scientists in that can show you what world records they'd make. So for example, we did another collaboration with the MRC, we made lots of our molecules, clinical molecules available to MRC scientists to try and find new indications for which then spurred the - NCATs was happening as well, and we’re one of the companies that has the most molecules, both clinical and preclinical in those types of things, you know when we set up the bio park in [inaudible 26:17], park, we had this huge site that was half empty and I used to wander through the corridors going from one group to the other and there would be those empty laboratories, they used to call it tumbleweed labs where you could hear the winds rushing through and it was a demoralizer and from the era when everyone was investing in bricks and infrastructure, bricks and mortar and infrastructure, because they thought they could just industrialize R&D and find out the very hard way that you couldn't, so then the organization shrank and we had these huge buildings. And so, what we did was we said – lets collapse our footprint on the building and let’s bring biotech’s in. So that was actually our first bio park and in contrast to other bio park cities, let’s not have the biotech’s that come in partitioned and walled off. Let’s have them using our cafeteria, our coffee shops, our shared spaces, let’s have them potentially using our equipment if they want to, so they have to buy capital, and we can really try and share our infrastructure, make ourselves good partners, help give them advice when they need it, if they need some regulatory advice some clinical advice, without asking for anything in return, it does start to encourage biotech’s to come in, it makes us again start to forge relationships with other companies and probably most importantly it starts to fill the space up and make you feel vibrant and energetic and full. Mike Rea:                          Which is an interestingly human approach – there's this great book called Obliquity which talks about getting what you want but approaching it in an oblique way and you're described a lot of internal and external signals about your readiness to embrace the future instead of the past. How important is that -? Dr. Menelas Pangalos:       And treat people like grown-ups, the other thing is treating people like grown-ups, because again when we first set this up they were like – what do you mean they're going to be wandering around – everyone signs a CDA, if they don't follow what they should be doing they’ll get kicked off the side, so I think if we go in with the assumption that everybody is going to behave themselves and actually follow the appropriate principles, then actually you're pretty safe. You don’t have to have barriers and passes and everything else, and actually we’ve done it in Boston, in Wharton and actually created – we had a half empty building in Boston which is now packed and actually has a waiting list for biotech’s to come in and in Gothenburg as well. Now in Cambridge it’s a little bit different because we’re already in the middle of the biotech cluster so it’s a little bit less important, but for those sites it’s a little bit more isolated and not right in the midst in Kendall square or not in England for example, in Sweden. It makes quite a big difference having this sort of vibrant environment.  Mike Rea:                          Kendall Square has almost become a hiring hub rather than an innovation spreading hub, because people aren’t necessarily collaborating there, just hiring the folks from –  Dr. Menelas Pangalos:       Well the nice thing about this – what I find about us being in Cambridge is you know–  you go to a coffee shop or you drop your kids off into school, and you bump into someone, happens to be a hematologist who has just come over, is working and you can start to talk about things that we couldn’t talk about when we were in Cheshire, because the environment is just different. So, it’s actually amazing, how many collaborations and relationships have been initiated through these informal connections. So one of the things that I've been trying to do over the years is try and generate as many opportunities for our scientists to have informal connections, whether it’s with people in the bio houses where the collaborators were, you're just making it easier for the serendipitous to happen and then again innovation can happen. Mike Rea:                          Yeah planning for serendipity. Absolutely. So, one of the things that's been apparent from the outside is the way that you've approached innovation as an active process and five hours is a very good illustration of that. Do you measure it year on year?  Dr. Menelas Pangalos:       So, we measure lots of things. I have got a great portfolio management group. I measure it but don’t necessarily incentivize on it. So, I think we measure how many proof of mechanisms we have done, we measure our proof of concepts, so obviously we get rewarded for things like phase III investment decisions and launches. We measure how many publications are coming out, from which groups. But I try not to get to, we tend to do - first full three-year holding averages, so no one is ever pressured into doing something in one year and getting a number. And actually, the focus really is on the quality of what people are doing, and how innovative is it, how inventive is it. Is it going to lead to hopefully to break through in the therapy area in terms of capability? Mike Rea:                          So, you have got trendlines rather than timelines. Dr. Menelas Pangalos:       Yeah so, we are quite careful about that because I just think it drives the wrong behavior if you are not careful. Mike Rea:                          Right, People start gaming whatever they are given as a target. Dr. Menelas Pangalos:       Sounds so brilliant doing that. You know you give whatever target you give them they are good at hitting them. Again, the CD one, it’s amazing what behave - in 2005 - 2010 period, because there were [inaudible 31:30] the number of backups we had in the pipeline. Backup number 1,2,3,4,5,6,7, then of course all the backups had exactly the same probability as the lead molecule. So, we don’t do backups anymore. Mike Rea:                          Right, I remember sitting in Sweden once, listening to the team saying that it doesn’t matter if this one doesn’t work because you have got a backup - how does that not matter? Just because you are in a job for another couple of years, but -  Dr. Menelas Pangalos:       Exactly right. Now unless it’s a really, really important program they know they are going to get one shot so they've got the time, they have got to work out the quality of the molecules versus taking a bit more time to get rid of a few more of the work. So, it’s a real balancing acta and for some plans we will have backups, but they are unusual. Less than 5% of our pipeline now has backups.   Mike Rea:                          Interesting times, and what’s been the biggest learning for you as a director of all of this activity over the period? Dr. Menelas Pangalos:       You know I've worked in different companies now, there's not a lot I would have done differently. I have seen Wyeth go through - before it was acquired by Pfizer, go through relatively similar transformations of what [inaudible 32:45] said of R&D, time was much more focused on a number of things. But he had a leadership team that was very passionate about science. And so, we were all very much focused on the quality of the science. I think the biggest piece is celebrating the wins, but also celebrating the good failures and then exemplifying them - constantly exemplifying the individuals, teams, projects. You know we were lucky that we had to grow in [inaudible 33:15] in particular, which came from our teams in Orderly Park actually which went from – you know we put the resources behind it and there was a new generation when I arrived and we moved it in the CD and then it went from CD to launch and in about three years, now that was a brilliant thing to have coming along because it was an example of what you can do.  And of course having a quick win, that also made the organization feel better about itself, Limpasa which was written off, we resurrected and brought back to line, even though we’ve never really stopped working on it and the Imed, when Pascal joined me asking me why is this not in phase III, suddenly pumped everyone's chest up and then everything we’ve been doing at Astra has been about rebuilding and then [inaudible 34:04] really well your artistic molecule. So, there's lot of really cool stuff in every area that we’re working in, of course that makes it easier to walk on and keep going.  Mike Rea:                          So, with what you described sounds like the early stage of an exponential growth rather than just seeing the results -  Dr. Menelas Pangalos:       I hope so. So, the other piece I love about our company is I think we are a humble company, starting with Pascal and his leadership team all the way through our leaders and our scientist. You know once we got better, I think - I have said this to you previously, we are still failing 80% of the time. Right so we have got lots of room for improvement and very few companies that have been able to continuously in 5 years cycles continue to be at the top end of the productivity chart. So, we have had a good 5 years. That is one set of 5 years so for me the huge chance is making sure we continue to do this. So, the pipeline continues to fuel new launches and new medicines, that No one in the organization gets complaced in any way- shape or form. They remain humble collaborative, open and porous to ideas whether they are from inside or outside. Mike Rea:                          Which has been an interesting characterization of the change I think and having that humility seems – adds more to AstraZeneca, in my external perception to where it is today. So, what drives you personally in this space? Dr. Menelas Pangalos:       I have always been - it’s difficult now not to think of myself as a leader, but I always used to get really upset when people called me a line manager or a leader versus scientist. I'm a scientist first and foremost. I get excited about seeing people’s data. Not the bullet points from the power points, the actual data. The graphs the –  Mike Rea:                          And a scientist in your approach to the day job as well, I guess. Dr. Menelas Pangalos:       There's a keenness, so I still have a couple of students and I don't spend anywhere near enough time with them but I’ve tried to keep my academic links, but more importantly it’s just to encouraging science, constantly encouraging science, constantly speaking to our scientists. Going and seeing their projects, seeing them present their posters, seeing and encouraging the next generation of science and scientist just to come through. To me that's the first driver is just the quality of the science and being an organization that you can say and be really proud is doing good science. Second one is about being collaborative. I’ve always been quite collaborative by nature and I get irritated actually by people that hoard data or think that they can't share things and so –  Mike Rea:                          Yeah, I’ve noticed cause you're active on twitter too that that's – how do you feel about that as a collaborative exchange. Dr. Menelas Pangalos:       It’s good so we’ve got this new thing called Workplace which is a spinoff from Facebook and its actually working really well, where you can start to post – so someone will post a bit of scientific data and then you can ask questions and you can generate – Twitter is a great place for – I see it more for news and getting people’s opinions on things that are coming out., particularly if they're from outside of AZ. But this being open to ideas wherever they come from and being porous and you can talk about being collaborative and then you can be collaborative and I really want it to be collaborative. So, I am probably being too open rather than less open. If I ever have to choose if it works for us, I think the risks are relatively small and the upside is huge. And then – there is two things, and then the other piece that I'm incredibly passionate about which – actually Katherine in the room here, was an example is developing our talent. So really I’ve seen it happen all through my career actually as I’ve grown through the industry, but surrounding yourself with people that are smarter than you are, but also pulling people up more rapidly, and I kind of think about my career journey and I’ve been lucky to have some managers that were quite – leaders that were prepared to take risks on me and sort of propelled me up the line, probably more quickly than I was ever expecting, not probably, a lot more than I was ever expecting, but some people getting there – you're sure about that? And I kind of have this same conversation with my leaders and their leaders about take risks on people. If you haven't got people in places that are a little bit uncomfortable and really pushing themselves and finding out they can really swim versus sign, you'll never accelerate people’s careers. So that's something that we spend quite a little time, with my team and their team. So, I spend a little time doing talent development and really trying to pull out the bright sparks faster than they would otherwise have moved Mike Rea:                          That's interesting. I’m going to ask Katherine; do we have two more minutes? I'm going do the 2-minute timeline. Okay so, within a spurt of a 2-minute rule, so what – you clearly read a lot, what books do you go back to as your core – which books do you recommend? Dr. Menelas Pangalos:       So, the one that's probably closest to my heart from a heartstring’s perspective is probably Roy Vagelos’s autobiography around Science, Medicine and Merck. Mike Rea:                          That was a great period. Dr. Menelas Pangalos:       And for me he was – apart from [inaudible 40:04] obviously a Greek heritage like I am, I’ve never had a scientist in my family, so reading his – I just read his book and it was just amazing what he did and Merck for me, as you know I was doing my PhD, that was the prototypical, what a great R&D organization looks like and I actually did a PhD that was sponsored by them and Roy was like a hero. He was one of the first science led CEO’s and he took a company and really to me he epitomized the science at organizations and so – that's probably one of my favorite discovery books that I read in kind of a – I’ve never actually met him, but I would love to meet him and I just think he did an amazing job and actually it so happened when Merck lost that science focus – they got it back now and I think it made a huge difference, that for me has been one of my guiding lights. All through my career. And then when I was at Wyeth actually I met Bill George for the first time and we’ve met him – I’ve been at AstraZeneca a few times, he’s written a book called Discover your True North and that's about what are your guiding principles, what are your true norths and sticking to them, well actually not sticking to them, knowing what they are so you can stick to them and that has been something that again I have used, when I first joined the company I wrote down my list of four or five things that were the most important things for me, but I never should have talked about over the past few minutes and sticking to those principles and not ever letting them go, because they're what define you, and have been really important. Mike Rea:                          Fantastic. And what are your ambitions for the next five years? Dr. Menelas Pangalos:       To do this. I think we have the best jobs in the world honestly. Scientists in the organization, we’re able to turn science into medicine and really see the impact of what we do and for me, I’ve completed part one of my journey at AstraZeneca, we now need to show that we can do it again, and that we can hopefully improve even further. It was something that we can continue through, I want to just keep doing that, I love doing what I'm doing. Mike Rea:                          Fantastic, and one thing that you wished that I’d ask you that I haven't asked you. That's the last question. Dr. Menelas Pangalos:       How do you relax? As I'm sure you know, you know from speaking to – these are pretty intense jobs, and so my family probably are the thing that brings me down to earth and you're talking about your kid being a guitarist, my kids they're young, they're nine and ten, my wife’s a scientist but they're all very good at when I come home to making me silly daddy and just bringing me completely down to earth and I find that the most relaxing thing out there, being with my family. Mike Rea:                          Excellent, well thank you so much and I know there's a thousand questions I could have continued to ask you. Hopefully we’ll get to do it again. Thanks.  Dr. Menelas Pangalos:       Thank you very much. 

THIS WEEK AT NO BS WITH SB #011 WE RECEIVE The comedian from Hamilton Canada

On this weeks show we have three hosts Maine, Josh and Ryan get on the microphones and Recap the weeks BJJ news and events. The team bring up Keenan Cornelius leaving Atos and potentially opening up his own school. We talk about Ralph Gracie being issued a warrant for his involvement in the IBJJF No-Gi worlds fight. We talk about the ADCC invites, Mahamed Aly changing divisions for ADCC going from -99kg to +99 kg. Plus we talk about Robert Whittaker entering the ADCC trials. After that we recap Fight to Win 109, in Baltimore Maryland. Josh competed on this card, this was his first broadcast professional event as a black belt. We talk about DJ Jackson, Shane Jamil Hill Taylor, the Judo matches, and a bunch of other grapplers from Baltimore, and Baltimore BJJ, as well as Form. Taking a look at Rob Sullivan, and Just the Tap BJJ owner David Brennan deep Kimura, and general arm nastiness that he was in during his match. The team had a great time at the event as always and cannot wait for it to come back around. After that we move into the previews section of the show taking a look at the Abu Dhabi UAEJJF Worlds Championships tons of big names, and tons of top competitors that will have to fight off in the Brazilian qualifier to even earn their spot into the world championship event. This event is always fireworks with the short match time, and penalty rules. We preview Fight to Win 110 in Cleveland Ohio featuring Jaime Canuto vs Michael Liera Jr, and an astonishing Co-Main Event in the Gi Stipe Micoc the most decorated UFC heavyweight champion vs Aaron Howard of Carlson Gracie team. Plus Max Gimenis vs Alexander Huddleston. As well as Troy Everett showing up on the card as well in Team No Sleep and Night Pigeon fashion. This event should be lots of fun as well. We briefly attempt to preview the Second ADCC European Trials, although at the time of this recording very little information is available on the event, aside from streaming time and dates. So instead we talk about the ADCC invites that came out this week, and talk about the remaining spots still available for ADCC 2019. We also do a preview of the Brothers 8- Man 150 lbs Woman's event taking place this weekend as well. Recorded 4-22-2019

In this episode of Map of the Maze we talk to David Brennan, CEO of Nexus Vehicle Management about his experience of delivering multiple private equity exits. The preparation needed before taking the business to market, driving pace and efficiency once the process has started, the due diligence you should undertake on your new owners and how to deliver some quick wins for your new investor!

On this episode of The Backbone, I chat with David about: What he attributes to being a part of many technology success stories and the advice he'd impart on finance leaders. The biggest difference between software and hardware technology companies and how it effects the capital raise or acquisition process? What Ecobee is all about, and how it became a global brand in home automation. About his passion towards people and their role in organizations; why its important in scaling organizations and why he cares so deeply about it as the finance leader? The importance of the finance function at a technology company. --- Send in a voice message: https://anchor.fm/backbone/message

As we think about what is wrong with the world, we can start diagnosing multiple potential problems. That kind of came across in my reading this week. There are plenty of things that we need to figure out if we are going to start fixing the world. Therefore, let's start figuring out what's wrong so we can worry about what's right. 1. One-Third of Americans Don't Believe 6 Million Jews Were Murdered during the Holocaust by David Brennan from Newsweek 2. Why Small Places Still Matter by Ryan Terry from The American Conservative 3. How to Disagree by Paul Graham from paulgraham.com. 4. You Are Not Perfect Just the Way You Are by Regis Nicoll from Crisis Magazine 5. Why Society Needs to Cultivate a True Elite Class by John Horvat from The Imaginative Conservative All music from audionautix.com.

Before we tell you about this episode, two quick things! First, Scene Partners is planning a live show! Book it in your calendars. On September 12th, Scene Partners will be recording their kick-off of Season 2. You can be part of the show and see some special guests from Season 1. Second, please rate and subscribe to the show. We love that. Now, back to what you've been waiting for. What's wrong with going to a sports bar? What's the worst service you've ever had at a restaurant and still tipped? If you had to get one cliched quote tattooed on your lower back, what would it be? These are a few of the big life questions tackled today. At one point, the conversation turns into a ridiculous debate about Madonna lyrics and you can imagine it's well informed. We are thrilled to have a very funny David Brennan on our show today. A sketch comedian, stand up veteran and one of the nicest dudes you've ever met.

Welcome aboard the Shuttle Tydirium Podcast for episode 71! This week we're taking a deep dive into the final mission of the Smuggler's Lament (C-ROC) campaign. Does it hold up under the crew's expert scrutiny? Ready Room: 14:50 Music in the dramatic reading is by Kai Engel, used under a creative commons license, (and adapted for our purposes by Phil Meade).  Check out Kai Engel’s excellent compositions here:  http://freemusicarchive.org/music/Kai_Engel/. If you really like his stuff put a buck in his tip jar!  Thanks to our Patrons Jan Ullerup, David Brennan, Steve Ruples, Kletus Van Dam, David Holland, and Tim LeBeau for lending their voice talents to the C-ROC campaign readings!  Facebook: FACEBOOK Gmail: the.shuttle.tydirium@gmail.com

Welcome aboard the Shuttle Tydirium podcast for episode 66!  We got our first look at the M-12 Tequila fighter this week, we talk a bit about the Global Grayskull campaign, and we also got into a very in-depth discussion of mission C2A, AKA 'Intel Raid', AKA 'The better Mission 2'. Captain's Question: 5:30 Global Grayskull Narrative Campaign: 17:00 M-12 Tequila fighter expansion preview: 21:25 Ready Room: 45:00 Music in the dramatic reading is by Kai Engel, used under a creative commons license, (and adapted for our purposes by Phil Meade).  Check out Kai Engel’s excellent compositions here:  http://freemusicarchive.org/music/Kai_Engel/. If you really like his stuff put a buck in his tip jar!  Thanks to our Patrons Jan Ullerup, David Brennan, Steve Ruples, Kletus Van Dam, David Holland, and Tim LeBeau for lending their voice talents to the C-ROC campaign readings!  Facebook: FACEBOOK Gmail: the.shuttle.tydirium@gmail.com

Welcome aboard the Shuttle Tydirium podcast for episode 64! This episode, we'll be covering a slew of questions from listeners, and then taking a crack at mission C2B: Prison Convoy! It's a mission with two boards - what could possibly go wrong! Captain's Question(s): Local Scene: 33:00 Ready Room: Mission C2B, Prison Convoy: 37:44 -Protocol Mode: 40:05   Music in the dramatic reading is by Kai Engel, used under a creative commons license, (and adapted for our purposes by Phil Meade).  Check out Kai Engel’s excellent compositions here:  http://freemusicarchive.org/music/Kai_Engel/  Thanks to our Patrons Jan Ullerup, David Brennan, Steve Ruples, Kletus Van Dam, David Holland, and Tim LeBeau for lending their voice talents to the C-ROC campaign readings!  Facebook: FACEBOOK   Gmail: the.shuttle.tydirium@gmail.com

Welcome aboard  the Shuttle Tydirium Podcast for Episode 63! This week we're starting our examination of the campaign included in the C-ROC expansion pack. This week, we'll be looking at mission one, as well as an... alternative version of mission one that certain members of the crew played. This we really make the mistakes so you don't have to!   Captain's Question: 3:30 Ready Room - Mission C1: The Deal Gets Worse: 10:28 -Dramatic Reading: 15:15 B-Team: 1:10:40   Music in the dramatic reading is by Kai Engel, used under a creative commons license, (and adapted for our purposes by Phil Meade).  Check out Kai Engel’s excellent compositions here:  http://freemusicarchive.org/music/Kai_Engel/  Thanks to our Patrons Jan Ullerup, David Brennan, Steve Ruples, Kletus Van Dam, David Holland, and Tim LeBeau for lending their voice talents to the C-ROC campaign readings!  Facebook: FACEBOOK   Gmail: the.shuttle.tydirium@gmail.com

Interview with David Brennan. He is the CEO of recommnded.com and has experience at Google, Infosys, and Robert Half. He believes candidate experience must be a priority.

David Brennan was CEO of AstraZeneca. He retired years ago, but was recently engaged to be an interim CEO for Alexion Pharmaceuticals, then transitioned into Chairman of the Board. Get inspired by David's tale.

In this podcast, Dr. David Brennan talks about his work in the development and evaluation of online outreach to address issues of gay and bisexual men’s health. To highlight this work, Dr. Brennan describes CRUISElab, a research lab focused on gay and bisexual men's health. He also talks about the "Cruising Counts" study, which has been essential in developing new guidelines for online health outreach to gay men in Ontario.

I talk with a fellow writer about how our nerdiness brought us toghether and defines our writing to this day.

The days of being tied to a desktop computer are long gone. Ecommerce merchants can work wirelessly with laptop computers, personal digital assistants, and increasingly, smart mobile phones. Quickoffice is a Texas-based software company which focuses on providing mobile office software. David Brennan is Quickoffice’s vice president of ecommerce . He speaks with Practical Ecommerce’s Kevin Patrick Allen.

David Brennan is a prophecy expert with fresh revelation from the Word of God. He has studied and made predictions based on the Bible and they've come to pass. What he has to share concerning the future of America will help you understand events ahead on God's prophetic time clock.

David Brennan is a prophecy expert with fresh revelation from the Word of God. He has studied and made predictions based on the Bible and they've come to pass. What he has to share concerning the future of America will help you understand events ahead on God's prophetic time clock.

David Brennan is a prophecy expert with fresh revelation from the Word of God. He has studied and made predictions based on the Bible and they've come to pass. What he has to share concerning the future of America will help you understand events ahead on God's prophetic time clock.

David Brennan is a prophecy expert with fresh revelation from the Word of God. He has studied and made predictions based on the Bible and they've come to pass. What he has to share concerning the future of America will help you understand events ahead on God's prophetic time clock.